Page last updated: 2024-11-13
ft011
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
FT011: an antifibrinolytic agent; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 23648966 |
| CHEMBL ID | 1075834 |
| SCHEMBL ID | 1590611 |
| SCHEMBL ID | 1590608 |
| MeSH ID | M0578919 |
Synonyms (27)
| Synonym |
|---|
| ft011 |
| CHEMBL1075834 |
| shp-627 |
| ft-11 |
| ft-011 |
| (e)-2-[[3-(3-methoxy-4-propargyloxyphenyl)-1-oxo-2-propenyl]amino]benzoic acid |
| (e)-2-[[3-(3-methoxy-4-(prop-2-ynyloxy)phenyl)-1-oxo-2-propenyl]amino]benzoic acid |
| UIWZIDIJCUEOMT-PKNBQFBNSA-N |
| SCHEMBL1590611 |
| SCHEMBL1590608 |
| CS-5842 |
| HY-100495 |
| (e)-2-(3-(3-methoxy-4-(prop-2-yn-1-yloxy)phenyl)acrylamido)benzoic acid |
| benzoic acid, 2-[[(2e)-3-[3-methoxy-4-(2-propyn-1-yloxy)phenyl]-1-oxo-2-propen-1-yl]amino]-;benzoic acid, 2-[[(2e)-3-[3-methoxy-4-(2-propyn-1-yloxy)phenyl]-1-oxo-2-propen-1-yl]amino]- |
| 1001288-58-9 |
| AKOS032945056 |
| N17095 |
| benzoic acid, 2-[[(2e)-3-[3-methoxy-4-(2-propyn-1-yloxy)phenyl]-1-oxo-2-propen-1-yl]amino]- |
| 2-(3-methoxy-4-propargyloxycinnamoyl)aminobenzoic acid |
| MS-25428 |
| C6V7ZU2NPR , |
| 2-(((2e)-3-(3-methoxy-4-(2-propyn-1-yloxy)phenyl)-1-oxo-2-propen-1-yl)amino)benzoic acid |
| benzoic acid, 2-(((2e)-3-(3-methoxy-4-(2-propyn-1-yloxy)phenyl)-1-oxo-2-propen-1-yl)amino)- |
| unii-c6v7zu2npr |
| 2-[[(e)-3-(3-methoxy-4-prop-2-ynoxyphenyl)prop-2-enoyl]amino]benzoic acid |
| BQB28858 |
| AC-35521 |
Research Excerpts
Overview
FT011 is an anti-inflammatory and anti-fibrotic agent. It attenuates organ damage in diabetic rats with cardiomyopathy and nephropathy.
| Excerpt | Reference | Relevance |
|---|---|---|
| "FT011 is an anti-inflammatory and anti-fibrotic agent that has been reported to attenuate organ damage in diabetic rats with cardiomyopathy and nephropathy." | ( FT011, a Novel Cardiorenal Protective Drug, Reduces Inflammation, Gliosis and Vascular Injury in Rats with Diabetic Retinopathy. Berka, DR; Deliyanti, D; Kelly, DJ; Khong, F; Stapleton, DI; Wilkinson-Berka, JL; Zhang, Y, 2015) | 2.58 |
Treatment
FT011 treatment in diabetic rats reduced glycogenin levels and, subsequently, renal glycogen concentration. FT011 did not change glycogen synthase or glycogen phosphorylase enzyme activities.
| Excerpt | Reference | Relevance |
|---|---|---|
| "FT011 treatment was associated with improved cardiac function (increased ejection fraction, fraction shortening and preload recruitable stroke work) and myocardial remodeling (reduced left ventricular diameter and volume at both end diastolic and systolic) compared with vehicle treatment." | ( A new anti-fibrotic drug attenuates cardiac remodeling and systolic dysfunction following experimental myocardial infarction. Cox, AJ; Edgley, AJ; Elsik, M; Gilbert, RE; Kelly, DJ; Khong, FL; Kompa, AR; Krum, H; Stapleton, DI; Tan, CY; Wang, B; Williams, SJ; Zammit, S; Zhang, Y, 2013) | 1.11 |
| "FT011 treatment in diabetic rats reduced glycogenin levels and, subsequently, renal glycogen concentration." | ( Attenuation of Armanni-Ebstein lesions in a rat model of diabetes by a new anti-fibrotic, anti-inflammatory agent, FT011. Kelly, DJ; Lau, X; Stapleton, DI; Zhang, Y, 2013) | 1.32 |
| "Treatment with FT011 did not change glycogen synthase or glycogen phosphorylase enzyme activities but prevented both glycogenin mRNA synthesis and accumulation of Armanni-Ebstein lesions in the diabetic kidney." | ( Attenuation of Armanni-Ebstein lesions in a rat model of diabetes by a new anti-fibrotic, anti-inflammatory agent, FT011. Kelly, DJ; Lau, X; Stapleton, DI; Zhang, Y, 2013) | 0.94 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (4)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID470779 | Reduction in albuminuria in STZ-induced Ren2 rat at 400 mg/kg/day after 24 hrs by radioimmunoassay | 2009 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 19, Issue:24 | Evaluation and optimization of antifibrotic activity of cinnamoyl anthranilates. |
| AID470778 | Reduction in albuminuria in STZ-induced Ren2 rat at 200 mg/kg/day after 24 hrs by radioimmunoassay | 2009 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 19, Issue:24 | Evaluation and optimization of antifibrotic activity of cinnamoyl anthranilates. |
| AID470773 | Antifibrotic activity in rat 1097 cells assessed as inhibition of TGF-beta-stimulated [3H]proline incorporation in to collagen at 100 uM | 2009 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 19, Issue:24 | Evaluation and optimization of antifibrotic activity of cinnamoyl anthranilates. |
| AID470774 | Antifibrotic activity in rat 1097 cells assessed as inhibition of TGF-beta-stimulated [3H]proline incorporation in to collagen at 30 uM | 2009 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 19, Issue:24 | Evaluation and optimization of antifibrotic activity of cinnamoyl anthranilates. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 33.02
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (33.02) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||